Regeneron Pharmaceuticals (MIC:REGN-RM) Construction In Progress : ₽0.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Regeneron Pharmaceuticals Construction In Progress?

Regeneron Pharmaceuticals's quarterly construction in progress increased from Sep. 2024 (₽0.00 Mil) to Dec. 2024 (₽185,245.88 Mil) but then declined from Dec. 2024 (₽185,245.88 Mil) to Mar. 2025 (₽0.00 Mil).

Regeneron Pharmaceuticals's annual construction in progress increased from Dec. 2022 (₽60,006.60 Mil) to Dec. 2023 (₽121,359.35 Mil) and increased from Dec. 2023 (₽121,359.35 Mil) to Dec. 2024 (₽185,245.88 Mil).

Regeneron Pharmaceuticals Construction In Progress Historical Data

The historical data trend for Regeneron Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Construction In Progress Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Construction In Progress

Get a 7-Day Free Trial

53,991.19

56,759.90

60,006.60

121,359.35

185,245.88

Regeneron Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Construction In Progress	Get a 7-Day Free Trial															-	-	-	185,245.88	-

Regeneron Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIC:REGN-RM) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 1REGN:Italy 0R2M:UK RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines